Trial Profile
A Phase 1 Dose-Escalation Study of SCH 900776 in Combination With Cytarabine in Subjects With Acute Leukemias (Protocol No. P05247)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; MK 8776 (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Merck & Co; Merck Sharp & Dohme
- 10 Dec 2011 Results have been reported at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
- 15 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Apr 2011 Planned end date changed from 1 May 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.